Vaccibody to change its accounting standard to IFRS (International Financial
Reporting Standards)

	Vaccibody to explore a potential listing of its shares on the Nasdaq Global
Market in the United States


Oslo, Norway, March 5, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of novel immunotherapies,
announced today that Vaccibody has decided to change its financial reporting
from NGAAP (Norwegian Generally Accepted Accounting Principles) and instead
adopt IFRS (International Financial Reporting Standards) as its new accounting
standard.

Vaccibody has experienced a continued growing international interest in its
stock, including a significant increase in its international investor base which
has led to the Company's decision to change its accounting standard to IFRS. The
above change will be adopted with effect from the Company's annual report as of
the financial year 2020. 

In addition, Vaccibody has initiated a process to explore a possible listing of
Vaccibody on the Nasdaq Global Market in the United States. This process
reflects the continued clinical and strategic advancement of Vaccibody's
portfolio of innovative vaccines and novel immunotherapies as well as the
growing interest of international investors in Vaccibody. The timing of any
potential listing will be considered as part of this review process and any
potential listing would be subject to prevailing equity capital markets
conditions at such possible relevant time.


About Vaccibody 
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies. The Company
develops vaccines for the treatment cancer and infectious diseases. Vaccibody's
vaccine technology specifically targets antigens to Antigen Presenting Cells,
which are essential for inducing rapid, strong and long-lasting antigen-specific
immune responses and elicit efficacious clinical responses. Its lead product
candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively
outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment
of melanoma, lung-, head and neck, renal-, and bladder cancer